Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Santi Suryani1, Lauryn S. Bracken1, Richard C. Harvey2, Keith C.S. Sia3, Hernan Carol1, I-Ming Chen2, Kathryn Evans1, Philipp A. Dietrich1, Kathryn G. Roberts3, Raushan T. Kurmasheva4, Catherine A. Billups5, Charles G. Mullighan6, Cheryl L. Willman2, Mignon L. Loh6, Stephen P. Hunger7, Peter J. Houghton4, Malcolm A. Smith8, and Richard B. Lock1

Abstract

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with the MEK inhibitor selumetinib, against JAK-mutated patient-derived xenografts. Patient-derived xenografts were established in immunodeficient mice from bone marrow or peripheral blood biopsy specimens, and their gene expression profiles compared with the original patient biopsies by microarray analysis. JAK/STAT and MAPK signaling pathways, and the inhibitory effects of targeted drugs, were interrogated by immunoblotting of phosphoproteins. The antileukemic effects of AZD1480 and selumetinib, alone and in combination, were tested against JAK-mutated ALL xenografts both in vitro and in vivo. Xenografts accurately represented the primary disease as determined by gene expression profiling. Cellular phosphoprotein analysis demonstrated that JAK-mutated xenografts exhibited heightened activation status of JAK/STAT and MAPK signaling pathways compared with typical B-cell precursor ALL xenografts, which were inhibited by AZD1480 exposure. However, AZD1480 exhibited modest single-agent in vivo efficacy against JAK-mutated xenografts. Combining AZD1480 with selumetinib resulted in profound synergistic in vivo cell killing, although these results were not translated in vivo despite evidence of target inhibition. Despite validation of target inhibition and the demonstration of profound in vivo synergy between AZD1480 and selumetinib, it is likely that prolonged target inhibition is required to achieve in vivo therapeutic enhancement between JAK and MEK inhibitors in the treatment of JAK-mutated ALL. Mol Cancer Ther; 14(2): 364–74. ©2014 AACR.

Introduction

Although the overall cure rate for the most common pediatric cancer, acute lymphoblastic leukemia (ALL) now approaches 90%, certain high-risk subtypes experience shorter remission duration and a significantly reduced likelihood of survival (1).

1Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia. 2Cancer Center, University of New Mexico, Albuquerque, New Mexico. 3Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4Center for Childhood Cancer, Nationwide Children's Hospital, Columbus, Ohio. 5Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 6Department of Pediatrics, University of California at San Francisco, San Francisco, California. 7University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, Colorado. 8CTEP/NCI, Bethesda, Maryland.

Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

S. Suryani and L.S. Bracken contributed equally to this article.

Corresponding Author: Richard B. Lock, Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, PO BOX B1, Randwick, Sydney, New South Wales 2031, Australia. Phone: 1800-685-686; Fax: 612-9662-6583; E-mail: rlock@cclia.unsw.edu.au

doi: 10.1158/1535-7163.MCT-14-0647 ©2014 American Association for Cancer Research.

Recent genome-wide studies have focused on the molecular characterization of these high-risk subtypes, including B-cell precursor ALL (BCP-ALL) harboring mutations in the Janus kinases (JAKs; JAK-mutated ALL; refs. 2–4). Activating mutations in the pseudokinase or kinase domains of JAK1, JAK2, or JAK3 were detected in approximately 10% of high-risk pediatric ALL cases, and are frequently accompanied by deletion of the IKZF1 gene. These cases also exhibit gene expression signatures similar to BCR-ABL1-positive ALL, despite the absence of BCR-ABL1 translocations (2–4). The presence of JAK mutations in pediatric ALL with this “Kinase-like” gene expression signature is also significantly associated with high expression of cytokine receptor-like factor 2 (CRLF2) and a dismal outcome (2–4).

JAK mutations and CRLF2 overexpression result in aberrant activation of downstream signaling pathways, including JAK/STAT, MAPK, and PI3K/protein kinase B (PI3K/AKT) pathways (5–10). Cross-talk between the JAK/STAT, MAPK, and PI3K pathways has also been shown to occur at multiple levels (11). Constitutive activation of the JAK/STAT pathway enhances the MAPK and PI3K signaling pathways, causes cytokine-independent cell survival and proliferation of lymphoid cells (4, 5, 9, 12), and is implicated in the progression of lymphoproliferative diseases such as ALL, as well as other cancers (11, 13, 14). Consequently, they are compelling pathways for the development of targeted therapeutics to improve cancer treatment.
Several small molecules with inhibitory activity against JAK family members have shown preclinical and clinical activity in the treatment of myeloproliferative neoplasms, which harbor the JAK2 V617F mutation, as well as other solid tumors (15–20). Although the JAK2 V617F mutation is different from those that occur in ALL, these mutations occur in the same region of the protein and are functionally analogous in vitro (4, 5). AZD1480 is an ATP-competitive small-molecule inhibitor of JAK1 and JAK2 that also shows some selectivity towards JAK3 (20, 21). AZD1480 was selected by the Pediatric Preclinical Testing Program (PPTP) for preclinical efficacy testing against a panel of xenografts established in immunodeficient mice that were derived from high-risk pediatric ALL patient subtypes, including those harboring JAK point mutations, JAK2 fusions, high CRLF2 expression, and a Kinase-like gene expression profile. This rationale was based on the success achieved with imatinib in the treatment of BCR-ABL1–positive leukemia (22).

The JAK1/2 inhibitor ruxolitinib was recently shown to exhibit greater in vivo efficacy against two Kinase-like pediatric ALL patient-derived xenografts with activation of the JAK/STAT axis (one via a BCR-JAK2 translocation) but without CRLF2 overexpression, compared with several xenografts derived from Kinase-like cases harboring JAK point mutations and CRLF2 overexpression (23). This observation suggests that alternative survival pathways activated by CRLF2 may result in reduced sensitivity of ALL cells with activated JAK/STAT signaling to single-agent JAK inhibitors. Therefore, because xenografts established from JAK-mutated/CRLF2-high ALL biopsies would also be expected to exhibit heightened activation of the MAPK and PI3K/AKT pathways in addition to JAK/STAT (4, 5, 9, 12), we sought to enhance antileukemic efficacy by targeting multiple signaling nodes using the combination of AZD1480 and the MEK inhibitor, selumetinib (AZD6244, ARRY-142886). Selumetinib is a potent small-molecule inhibitor of MEK1/2, which blocks ERK1/2 activation (24). Despite strong evidence of in vitro synergy between AZD1480 and selumetinib, both drugs exhibited modest in vivo single-agent and combination efficacy. These findings highlight the complexity of translating in vitro synergistic drug combinations to the in vivo setting, and suggest that prolonged target inhibition may be required to achieve in vivo therapeutic benefit using JAK inhibitors for the treatment of pediatric ALL cases harboring JAK point mutations and high CRLF2 expression.

Materials and Methods

Patient and xenograft details

Pretreatment leukemia specimens were obtained from 21 children with high-risk BCP-ALL enrolled in the Children’s Oncology Group (COG) P9906 clinical trial, and were molecularly characterized by the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative (Table 1; ref. 3). Procedures by which continuous xenografts are routinely established from childhood ALL biopsies in female 6–8-week-old 20–25 g immunodeficient NOD/SCID (NOD.CB17-Prkdcsld/Sel) or NOD/ SCID/IL-2 receptor gamma null (NOD.Cg-Prkdcsld Il2rgtm1Wyl/Sel, NSG) mice, and criteria for determining successful engraftment, have been described in detail previously (25–27). Additional established BCP-ALL (ALL-4, ALL-10 [JAK1/V617F], ALL-19, ALL-25 and ALL-26) and T-ALL (ALL-31) xenografts were included in this study (26). JAK mutations are detailed where annotated.

Affymetrix U133_Plus_2.0 expression arrays

RNA from 38 xenograft samples was isolated from cryopreserved cells, labeled, and hybridized to Affymetrix U133_Plus_2.0 arrays as previously described (2). These new data, and the 13 parental samples analyzed in our prior study, were also masked and normalized by MAS5 as previously reported (2). The gene expression dataset can be accessed via Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession numbers GSE11877 and GSE58290. The xenograft samples were scanned in 2011, whereas the parent samples were scanned in 2006. The results for the 3 microarray quality control inclusion criteria are provided in Supplementary Table S1. Samples were retained only if all 3 conditions were satisfied: scale factors <35; GAPDH 3’ signal for M33197 >15,000; and, the GAPDH 3’/5’ ratio < 3.5. All but one of the xenografts (XRL_24) met these conditions.

Of the 54,675 probe sets on the Affymetrix U133_Plus_2.0 array, 89 represent X- and Y-specific transcripts associated with sex, 62 are Affymetrix controls, and 20 are globins. Removal of these resulted in 54,504 potentially informative probe sets. The average median expression across all the arrays was 173. A minimally interpretable expression level of 500 (~3-fold background) was established and all values <500 were set to a baseline of 500 for subsequent analysis. A total of 18,090 probe sets (33.2%) showed no signals greater than this baseline for any of the samples, leaving 36,414 probe sets for a comparison of xenografts to parental samples.

Quantitative RT-PCR

One microgram of total RNA was converted to cDNA using the High Capacity cDNA kit (Life Technologies). This was diluted to 50 μl and mixed with an equal volume of TaqMan Universal Master Mix II without UNG (Life Technologies). The 24 genes and an endogenous control gene (EEF2) were selected from the group of inventoried assays (available upon request) and were plated on custom microfluidic cards (Life Technologies). The sample ports were filled with the cDNA/master mix and the cards were sealed and run on an ABI model 7900HT instrument using the following parameters: 94.5°C for 10 minutes followed by 40 cycles of 97.0°C for 30 seconds and 59.7°C for 1 minute. A manual Ct threshold of 0.2 and automatic baseline were applied as analysis settings. The raw Ct value for the endogenous control sample, EEF2, was required to be <30. The ΔCt values were calculated by subtracting the EEF2 Ct from each gene’s Ct. Even though most samples had EEF2 Ct values much less than 30, a maximum ΔCt of 10 was applied to all gene intensities to permit equivalent treatment across all samples.

Statistical and analytical software

Affymetrix microarray data were analyzed using Expression Console (build 1.3.0.187, Affymetrix). Microfluidic cards were analyzed using SDS 2.4.1 software (Life Technologies). Heatmaps were created using MATLAB and its Bioinformatics toolbox (R2013b; MathWorks).

In vitro culture and drug treatments

Xenograft cells were removed from cryostorage and resuspended in QBSF-60 medium (Quality Biological) supplemented with F-3 ligand (20 ng/mL), penicillin (100 U/mL), streptomycin (100 μg/mL), and L-glutamine (2 mmol/L). Viability was determined by Trypan blue exclusion. Before treatment, cells were plated in 96-well plates (100 μl/well) at a density previously

www.aacnjournals.org Mol Cancer Ther; 14(2) February 2015 365

Efficacy of AZD1480 against JAK-Mutated ALL
<table>
<thead>
<tr>
<th>Xenograft</th>
<th>JAK status</th>
<th>CRLF2 status</th>
<th>Kinase-like</th>
<th>Other kinase lesions</th>
<th>Sample origin</th>
<th>Number of mice inoculated</th>
<th>Number of mice engrafted</th>
<th>Continuous xenograft</th>
<th>AZD1480</th>
<th>AZD1480</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK1 T6-46F</td>
<td>Normal</td>
<td>High</td>
<td>IGH@-CRLF2</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
</tr>
<tr>
<td>PAKJN</td>
<td>JAK1 S7-89P</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>PAKXJ</td>
<td>Wild-type</td>
<td>High</td>
<td>IGH@-CRLF2</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
</tr>
<tr>
<td>PAKJPK</td>
<td>Wild-type</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>ALL-4</td>
<td>Wild-type</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>ALL-10</td>
<td>JAK1 T658L</td>
<td>High</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>ALL-19</td>
<td>Wild-type</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>ALL-25</td>
<td>Wild-type</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>ALL-26</td>
<td>Wild-type</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>T-ALL-31</td>
<td>Wild-type</td>
<td>Normal</td>
<td>Yes</td>
<td>IGF1, PAX5, CDKN2A/B</td>
<td>BM</td>
<td>12</td>
<td>Yes</td>
<td>12.7 PD2</td>
<td>5.0</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BM, bone marrow; LGD, leukemia growth delay; NA, not applicable; ORM, objective response measure; PB, peripheral blood; PD, progressive disease.

Values shown are AZD1480 single agent as part of the AZD1480/AZD6244 combination study. The dose was attenuated to 30 mg/kg twice daily Monday to Friday for 2 weeks.
optimized (3–6 × 10⁶/mL) and equilibrated overnight at 37°C in 5% CO₂. Cells were exposed to 10-fold serial dilutions of AZD1480 or selumetinib (AstraZeneca; 10⁻⁶ to 10⁻¹² mol/L) for 72 hours, following which AlamarBlue reagent (Life Technologies) was added and fluorescence was measured at 0, 6, and 24 hours using a fluorescent plate reader (VICTOR³; PerkinElmer; excitation 560 nm, emission 590 nm). For fixed ratio combination assays, cells were treated with AZD1480 and selumetinib, alone or in combination, at 4, 2, 1, 0.5, 0.25, and 0.1 μmol/L. The combination drug effect was assessed using CalcuSyn software (Version 2.0, Biosoft) to calculate combination indices (CI) indicative of synergy (CI < 1), additivity (CI = 1), or antagonism (CI > 1).

**In vivo drug treatments**

AZD1480 and selumetinib were obtained from AstraZeneca under a standard Materials Transfer Agreement. Structures of both drugs are shown in Supplementary Fig. S1. Groups of 8 to 10 mice under a standard Materials Transfer Agreement. Structures of both drugs were incubated with 5 × 10⁶ xenograft cells retrieved from cryostorage, and engraftment monitored by weekly enumeration of the proportion of human CD45⁺ cells in the peripheral blood (%huCD45⁺; refs. 26, 27). Drug treatments were initiated when the median %huCD45⁺ exceeded 1% for each cohort. For single-agent in vivo efficacy testing, AZD1480 was administered by oral gavage twice daily at 10 mg/kg for 5 days, followed by a single daily dose of 15 mg/kg for 2 days. This cycle was repeated 3 times. For the combination efficacy study selumetinib (25 mg/kg) was administered 3 hours before AZD1480 (30 mg/kg), and both drugs were administered once daily by oral gavage Monday to Friday for 2 weeks and were dissolved in 0.5% hydroxypropyl methylcellulose and 1% Tween-80, with the pH adjusted to 3.0 for AZD1480. A preliminary tolerability study on nonengrafted mice had shown that this was the maximum tolerated dose and schedule of the combined drugs.

Following randomization of mice and the initiation of drug treatment, the %huCD45⁺ was measured weekly. Individual mouse event-free survival (EFS) was calculated as the day from treatment initiation until the %huCD45⁺ reached 25%. The EFS was represented graphically by Kaplan–Meier analysis and survival curves were compared by log-rank test. The efficacy of the drug treatment was evaluated by leukemia growth delay (LGD), calculated as the difference between the median EFS of the drug-treated cohort and the median EFS of the vehicle-treated cohort. An objective response measure (ORM), modeled after stringent clinical criteria, was assigned to individual mice, which allowed the determination of a median group ORM as described previously (25). Detailed methodology is presented in the Supplementary Methods and Supplementary Table S2. Correlations between in vivo and in vitro drug sensitivity were assessed by Spearman test. To evaluate interactions between drugs in vivo, Therapeutic Enhancement was defined as the EFS of mice treated with the drug combination being significantly greater than both single agents used at their maximum tolerated doses (28, 29).

**Analysis of protein expression**

Methods for preparation of whole-cell extracts, determination of protein concentrations, and analysis of cellular proteins by immunoblotting have been described in detail elsewhere (30). Antibody details can be provided upon request. Ba/F3TEL-JAK2-positive control cells were kindly provided by Dr. Chris Burns (Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia).

**In vivo pharmacodynamic analysis**

Mice were inoculated with PAMDRM xenograft cells, and monitored until the %huCD45⁺ reached ≥25%. The following treatment was administered with three mice per group per time-point: (i) vehicle control; (ii) one dose of AZD1480 (30 mg/kg); (iii) one dose of selumetinib (25 mg/kg); and (iv) one dose of selumetinib (25 mg/kg) 3 hours before one dose of AZD1480 (30 mg/kg). Spleen, peripheral blood (PB), and bone marrow (BM) samples were collected at 2 and 9 hours post-AZD1480 treatment for phosphorylated protein analysis by immunoblotting as described above.

**Results**

**Development and characterization of xenografts derived from JAK-mutated pediatric ALL biopsies**

Of the original 21 bone marrow or peripheral blood biopsy specimens inoculated from the P906 study, 15 showed evidence of engraftment in at least 2 mice using previously defined criteria (Table 1; ref. 27). This engraftment efficiency was lower than expected (27), and closer inspection revealed a distinct relationship between high CRLF2 expression and engraftment potential in this subset of high-risk ALL samples (Supplementary Fig. S2). The proportion of mice engrafted with CRLF2 high samples was significantly greater than CRLF2 normal samples (P = 0.023). Similarly, higher levels of spleen (P = 0.036), peripheral blood (P = 0.043), and bone marrow (P = 0.019) infiltration were observed in the CRLF2 high compared with CRLF2 normal xenografts. The gene expression profiles of spleen-derived cells from primary xenografts of 37 mice representative of 13 patient samples were then analyzed in relation to the original biopsy (parental) specimen.

Supplementary Table S1 lists the 13 parent samples and their corresponding xenografts analyzed at first passage. In addition, partial clinical information on the underlying lesions in the parental sample is provided in Table 1. The lesions and mutations of these parental samples have been previously characterized and reported as part of a larger study by Roberts and colleagues (6). Eleven of the 13 parents have CRLF2 lesions (9 IGH-CRLF2 and 2 P2RY8-CRLF2) with all but one of these (PALTWS) also having a JAK mutation. Each of the two cases without a CRLF2 lesion has a different kinase-related lesion (NUP214-ABL1 or IL7R mutation with SH2B3 deletion). Overall, eleven of the 13 parents also are considered Kinase-like on the basis of their gene expression pattern. The two primary leukemias that are not Kinase-like (PALNTB and PAITWS) both have IGH–CRLF2 translocations.

Overall, the quality of the xenograft samples was much better than the parent samples for scale factor and GAPDH expression: median xenograft scale factor 6.0 v. 15.9 and median GAPDH 63,272 v. 49,762 for the xenografts and parents, respectively (Supplementary Table S1). The median 3′:5′ ratios were comparable for the parents and xenografts (1.2 and 1.3, respectively; Supplementary Table S1). Despite the 5-year gap between analyzing the parent and xenograft samples, and the different lots of materials, there appeared to be no obvious large differences in the arrays. Supplementary Fig. S3 shows the distribution of expression levels for the 54,504 probe sets across all the parent samples.
Continuous xenografts have been established from 11 of the 15 primary xenografts following inoculation of spleen-derived cells into secondary and tertiary recipient mice (Table 1). Spleen-derived cells from the secondary and/or tertiary engrafted mice were used in the experiments described below.

AZD1480 inhibits aberrant JAK/STAT signaling in JAK-mutated xenografts

Because previous studies have shown that JAK mutations result in aberrant signaling via the JAK/STAT, MAPK, and PI3K/AKT pathways (2–5, 14, 31), we analyzed basal expression levels of key phosphoproteins as a surrogate for pathway activation in the xenograft panel. JAK-mutated xenografts exhibited increased signaling in JAK/STAT, MAPK, and PI3K/AKT signaling relative to xenografts ALL-25 and ALL-26, which have no annotated JAK mutations, as shown by elevated levels of pJAK1, pJAK2, pSTAT1, pSTAT3, pSTAT5, pMEK1/2, and pAKT (Fig. 2A). Elevated levels of these phosphoproteins were not uniform across all JAK-mutated xenografts.

The ability of AZD1480 to inhibit JAK/STAT signaling was tested across three JAK-mutated xenografts (PAKHZT, PAKRSL, and PALNTB) and compared with a xenograft harboring an activating translocation in JAK2 (BCR-JAK2, PAKYEP), as well as a xenograft with lesions in IL7R and SH2B3 (PALJDL). AZD1480 broadly decreased levels of pSTAT1/3/5 across the xenografts (Fig. 2B). In contrast, AZD1480 had minimal effects on pMEK1/2 and pAKT levels in all xenografts with the exception of PALJDL, which showed decreased levels of these phosphoproteins. Phosphorylation of ERK1/2 was also reduced in 3 of 5 xenografts tested (PAKHZT, PAKRSL, and PALJDL).

AZD1480 exerts variable antileukemic efficacy in vitro and in vivo

To gain additional evidence for the use of JAK inhibitors such as AZD1480 for the treatment of patients with JAK-mutated ALL, we tested its in vitro and in vivo efficacy against representative xenografts. The in vitro IC_{50} values for xenografts ranged from 0.6–5.0 µmol/L for 5 xenografts, to >10 µmol/L for the remaining 6 tested (Table 1; Fig. 2C and D and Supplementary Fig. S5). The 5 most sensitive xenografts (PAKHZT, PAKSWW, PAKYEP, PALJDL, and ALL-10 Jak/V658L), including that with BCR-JAK2 fusion (PAKYEP) and wild-type JAK (PALJDL), did not appear to conform to any specific JAK mutational status. Moreover, the differences in AZD1480 in vitro sensitivity did not appear to relate to differential inhibition of the JAK/STAT and MAPK signaling pathways, as described above and in Fig. 2B.

When tested in vivo as a single-agent AZD1480 induced significant progression delays in 3 of 10 of the JAK-mutated xenografts (Table 1; Fig. 3, Supplementary Table S6 and Supplementary Fig. S6). Despite some evidence of activity in delaying leukemia progression, AZD1480 was unable to elicit objective responses (modeled after stringent clinical criteria) in any of the xenografts regardless of their JAK status (all were scored as Progressive Disease, PD1 or PD2). A complete summary of results is provided in Table 1, Supplementary Tables S6 and S9, including total numbers of mice, number of mice that died (or were otherwise excluded), numbers of mice that reached event, average time to event, LGD values, as well as numbers in each of the ORM categories and median ORM values.
Rational targeting of the JAK/STAT and MAPK pathways to achieve synergistic antileukemic efficacy

Because of the modest single-agent activity exhibited by AZD1480 in vitro and in vivo, we investigated the potential for combination with other pathway inhibitors. As JAK-mutated ALL cells and JAK wild-type with a Kinase-like signature exhibited aberrant JAK/STAT and MAPK signaling (Fig. 2A and B), but modest inhibition of MAPK signaling by AZD1480 alone (Fig. 2B), we tested the combination of AZD1480 with selumetinib. Fixed ratio in vitro cytotoxicity assays revealed that the AZD1480/selumetinib combination exerted strong to very strong synergistic effects in 4 of 5 JAK-mutated ALLs (PAKRSL, PALJCF, PALLSD, and PAMDRM; average CI values <0.14; Fig. 4A–D and J, Supplementary Table S7). Synergism and moderate synergism were also observed with ALL-10JAK1/V658L (CI = 0.34) and PALJDL (CI = 0.73), respectively (Fig. 4E and I and Supplementary Table S7). In contrast, antagonism was observed for ALL-4, ALL-19 and ALL-26 (CI values > 1; Fig. 4F–H and J and Supplementary Table S7). Significantly greater synergy between AZD1480 and selumetinib was observed in the JAK-mutated compared with the JAK wild-type xenografts (P = 0.036; Fig. 4K). Of note, selumetinib alone exerted poor single-agent activity against all xenografts tested (IC50 > 10 μmol/L; Fig. 4A–I), regardless of their JAK mutational status.

The combined effects of AZD1480 and selumetinib were also assessed by phosphoprotein analysis of the PALLSD and PAMDRM xenografts. Consistent with the results presented in Fig. 2B, AZD1480 alone markedly decreased STAT1/3/5 phosphorylation (Fig. 4L and M). Selumetinib alone exerted minimal effects on levels of phosphorylated STATs, but substantially decreased pERK1/2 levels in both xenografts. Reduced levels of pSTAT1/3/5 and pERK1/2 were maintained or even enhanced with combination treatment for up to 24 hours in both xenografts. Minimal changes in pAKT were observed throughout the 24-hour treatment period for both xenografts.

Because of the strong synergy observed between AZD1480 and selumetinib against JAK-mutated xenografts in vitro, the combination was tested in vivo against xenografts PALLSD and PAMDRM, which both exhibited very strong synergism in vitro (Supplementary Table S7). Although AZD1480 alone delayed the progression of PAMDRM by 10 days, it did not delay the leukemia progression of PALLSD with both responses categorized as PD1 (Fig. 5A and B, Table 1; Supplementary Tables S8–S9). Selumetinib alone exerted no significant antileukemic efficacy against either xenograft. Despite the combination of AZD1480 and selumetinib exerting a significant progression delay in PAMDRM in comparison with vehicle-treated control and selumetinib alone, no objective responses or Therapeutic Enhancement were observed. The combined effects of AZD1480 and selumetinib were also assessed by phosphoprotein analysis of the PALLSD and PAMDRM xenografts. Consistent with the results presented in Fig. 2B, AZD1480 alone markedly decreased STAT1/3/5 phosphorylation (Fig. 4L and M). Selumetinib alone exerted minimal effects on levels of phosphorylated STATs, but substantially decreased pERK1/2 levels in both xenografts. Reduced levels of pSTAT1/3/5 and pERK1/2 were maintained or even enhanced with combination treatment for up to 24 hours in both xenografts. Minimal changes in pAKT were observed throughout the 24-hour treatment period for both xenografts.

Because of the strong synergy observed between AZD1480 and selumetinib against JAK-mutated xenografts in vitro, the combined effects of AZD1480 and selumetinib were also assessed by phosphoprotein analysis of the PALLSD and PAMDRM xenografts. Consistent with the results presented in Fig. 2B, AZD1480 alone markedly decreased STAT1/3/5 phosphorylation (Fig. 4L and M). Selumetinib alone exerted minimal effects on levels of phosphorylated STATs, but substantially decreased pERK1/2 levels in both xenografts. Reduced levels of pSTAT1/3/5 and pERK1/2 were maintained or even enhanced with combination treatment for up to 24 hours in both xenografts. Minimal changes in pAKT were observed throughout the 24-hour treatment period for both xenografts.

The combined effects of AZD1480 and selumetinib were also assessed by phosphoprotein analysis of the PALLSD and PAMDRM xenografts. Consistent with the results presented in Fig. 2B, AZD1480 alone markedly decreased STAT1/3/5 phosphorylation (Fig. 4L and M). Selumetinib alone exerted minimal effects on levels of phosphorylated STATs, but substantially decreased pERK1/2 levels in both xenografts. Reduced levels of pSTAT1/3/5 and pERK1/2 were maintained or even enhanced with combination treatment for up to 24 hours in both xenografts. Minimal changes in pAKT were observed throughout the 24-hour treatment period for both xenografts.

The combined effects of AZD1480 and selumetinib were also assessed by phosphoprotein analysis of the PALLSD and PAMDRM xenografts. Consistent with the results presented in Fig. 2B, AZD1480 alone markedly decreased STAT1/3/5 phosphorylation (Fig. 4L and M). Selumetinib alone exerted minimal effects on levels of phosphorylated STATs, but substantially decreased pERK1/2 levels in both xenografts. Reduced levels of pSTAT1/3/5 and pERK1/2 were maintained or even enhanced with combination treatment for up to 24 hours in both xenografts. Minimal changes in pAKT were observed throughout the 24-hour treatment period for both xenografts.

The combined effects of AZD1480 and selumetinib were also assessed by phosphoprotein analysis of the PALLSD and PAMDRM xenografts. Consistent with the results presented in Fig. 2B, AZD1480 alone markedly decreased STAT1/3/5 phosphorylation (Fig. 4L and M). Selumetinib alone exerted minimal effects on levels of phosphorylated STATs, but substantially decreased pERK1/2 levels in both xenografts. Reduced levels of pSTAT1/3/5 and pERK1/2 were maintained or even enhanced with combination treatment for up to 24 hours in both xenografts. Minimal changes in pAKT were observed throughout the 24-hour treatment period for both xenografts.
observed. A complete summary of all in vivo results is provided in Supplementary Tables S6, S8, and S9.

Pharmacodynamic evaluation of AZD1480 and selumetinib in leukemia-engrafted mice

In an effort to understand our inability to translate the profound in vitro synergistic interactions between AZD1480 and selumetinib to the in vivo setting, we evaluated signaling pathways by phosphoprotein immunoblots of PAMDRM cells harvested from the spleens of highly engrafted mice following drug treatment. Although both drugs alone and in combination profoundly reduced pSTAT1/3/5, and pERK1/2 levels at 2 hours after treatment, they had increased markedly at 9 hours in the control treatment, indicating that these xenografts provide a valuable resource for preclinical experimental therapeutics.

Previous reports have identified dysregulation of multiple key signaling pathways in Kinase-like ALL (6, 13), while Tasian and colleagues reported that both JAK/STAT and PI3K/mTOR pathways are activated in CRLF2-rearranged BCP-ALL (9). The JAK-mutated ALL xenografts established in this study also exhibited constitutive activation of JAK/STAT, MAPK, and PI3K/AKT pathways in contrast to BCP-ALL xenografts. Thus, the expectation was that pharmacologic inhibition of the JAK/STAT pathway with AZD1480 in JAK-mutated xenografts would result in substantial in vitro and in vivo antileukemic efficacy. However, despite evidence that AZD1480 inhibited JAK/STAT signaling both in vitro and in vivo, it exerted modest antileukemia efficacy and significantly delayed the progression of only 3 of 10 xenografts in vivo. With the exception of one xenograft with BCR-JAK2 fusion (PAKYEP) and one xenograft with JAK wild-type (PALJDL), the extent of leukemia progression is consistent with that reported for the JAK1/2 inhibitor ruxolitinib against JAK-mutated ALL (6, 23). Previously, significant decreases in leukemia burden were observed when mice engrafted with PAKYEP and PALJDL were treated with ruxolitinib (23). One possible explanation for the difference in efficacy between the two studies is that ruxolitinib was administered by continuous subcutaneous infusion, while we administered AZD1480 by oral gavage once or twice daily. As demonstrated in this study, the inhibitory effects of 10 mg/kg AZD1480 lasted between 2 and 9 hours in vivo.

Discussion

Patient-derived xenografts are increasingly recognized as important tools for understanding tumor biology and optimizing new treatments. This study describes the development and molecular characterization of a large panel of xenografts derived from a cohort of high-risk patients with Kinase-like gene expression signatures, most of which harbor JAK mutations. The concordance in gene expression profiles between xenografts and parent biopsies is remarkable, considering the number of uncontrollable variables associated with analysis of the batches of samples several years apart, indicating that these xenografts provide a valuable resource for preclinical experimental therapeutics.

![Figure 2. Aberrant signaling pathways in JAK-mutated xenografts and their inhibition by AZD1480. A, immunoblots of signaling proteins involved in the JAK/STAT, MAPK, and PI3K/AKT pathways in a panel of JAK-mutated and JAK wild-type xenografts. Ba/F3TL-JAK2 cells were included as positive controls. B, effects of in vitro AZD1480 treatment (1 μmol/L, 1 hour) on signaling proteins in JAK mutated and JAK wild-type with a kinase-like signature xenograft cells. C and D, in vitro sensitivity of xenograft cells to single-agent AZD1480. Representative cytotoxicity curves of a resistant (PAKWSW) and sensitive (PALSE) xenograft are shown. Following exposure of cells to various AZD1480 concentrations for 72 hours, viability was determined by AlamarBlue assay. Each data point represents the mean ± SEM of 3 independent experiments.](image-url)
Therefore, the lack of any observed objective responses in the current study when stringent objective response criteria developed by the Pediatric Preclinical Testing Program (25) were applied indicates that prolonged target inhibition is likely to be required to achieve significant therapeutic benefit. Furthermore, the apparent increased sensitivity of xenografts PAKYEP and PALJDL to both ruxolitinib and AZD1480 in vivo suggests that Kinase-like ALL cells with normal CRLF2 expression are more dependent on the JAK/STAT pathway than those with JAK point mutations and high CRLF2 expression.

Recent reports have highlighted compensatory activation of signaling pathways in response to inhibition of a single kinase node, and the successful targeting of dual pathways to achieve therapeutic synergy (32–34). Therefore, we explored dual inhibition of the JAK/STAT and MEK pathways in JAK-mutated ALL xenografts to improve the in vitro and in vivo antileukemic efficacy of a JAK inhibitor when used alone. We observed potent synergistic cell killing in vitro with the AZD1480/selumetinib combination at submicromolar concentrations, suggesting that both the JAK/STAT and MAPK pathways are critical for the survival of JAK-mutated ALL. There was also evidence for selectivity in this synergy against JAK-mutated/Kinase-like xenografts, as synergy was not observed in 4 xenografts with wild-type JAK (Fig. 4I). However, despite the AZD1480/selumetinib combination significantly delaying the progression of one JAK-mutated xenograft, no objective responses were achieved. These results, along with our additional in vitro combination cytotoxicity experiments and pharmacodynamics study, suggest that prolonged pathway inhibition is required in order to achieve synergy between AZD1480 and selumetinib.

The plasma half-life ($t_{1/2}$) of AZD1480 was approximately 2 and 5 hours in mouse models (21) and humans (35), respectively. However, whereas the human study showed maximal pSTAT inhibition in circulating granulocytes at 1 to 2 hours postadministration (35), a murine Ba/F3 TEL-JAK2 model showed prolonged pSTAT5 inhibition for up to 12 hours in spleen-derived cells upon administration of a 30 mg/kg dose, consistent with significant in vivo antileukemic efficacy (21). In the same study, pSTAT5 suppression was observed to a maximum of 8 hours at the 10 mg/kg dose, consistent with our findings. The $t_{1/2}$
Synergism antagonism

of selumetinib in humans was a median of 8.3 hours (36), and increased with increasing dose, while sustained inhibition of pERK was observed in circulating lymphocytes from patients treated on a prolonged twice daily dosing regimen. The rapid plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib, along with our inability to coadminister the higher doses more frequently than plasma clearance of AZD1480 and selumetinib. Despite the disappointing outcome of our efficacy experiments testing the in vivo combination of AZD1480 and selumetinib, other JAK inhibitors may be useful for the treatment of JAK-mutated ALL. Although the clinical development of AZD1480 has recently been halted due to dose-limiting toxicities (35), our data clearly demonstrate that AZD1480 was able to inhibit its target in vivo, albeit briefly. Other JAK inhibitors such as ruxolitinib, TGT101348, and CYT387 have demonstrated clinical safety and efficacy in other malignancies (16, 17, 38), and ruxolitinib in

Figure 4. Combination effects of AZD1480 and selumetinib on cell survival and signaling pathways in ALL xenografts. A–H, sensitivity of JAK-mutated (A–E) and JAK wild-type (F–I) xenografts to in vitro fixed ratios of single agents and the combination of AZD1480 and selumetinib. After 72 hours, drug exposure cell viability assessed by AlamarBlue assay. Each data point represents the mean ± SEM of 3 independent experiments. J, Log10 CIs from xenografts shown in A–I, represented as mean ± SE, K, mean CIs of JAK-mutated and JAK wild-type xenografts were compared using the Student t test. L and M, Log10 CIs from xenografts shown in A–I, represented as mean ± SE. K, mean CIs of JAK-mutated and JAK wild-type xenografts were compared using the Student t test.
particular was efficacious against preclinical models of pediatric JAK-mutated ALL (23, 39). Thus, alternative JAK inhibitors, when used under conditions that can achieve prolonged target inhibition, may yet be efficacious in the treatment of JAK-mutated ALL.

In summary, this study has detailed the development and molecular characterization of a panel of patient-derived xenografts from Kinase-like/JAK-mutated pediatric ALL. These xenografts exhibited dysregulated activation of multiple signaling pathways, consistent with the primary disease, indicating that they provide a highly relevant preclinical experimental model. Despite strong evidence of target inhibition, a small-molecule JAK1/2 inhibitor exhibited modest in vitro and in vivo antileukemic efficacy against these xenografts, leading to rational targeting of dual signaling nodes that resulted in profound in vitro drug synergy. Translation of these synergistic drug interactions to the in vivo setting, however, appeared to require sustained target inhibition that was not achievable using tolerable drug dosing and administration schedules in experimental mouse models.

Disclosure of Potential Conflicts of Interest
M.I. Loh is a consultant/advisory board member for Novartis. No potential conflicts of interest were disclosed by the other authors.

Disclaimer
Children's Cancer Institute Australia for Medical Research is affiliated with UNSW Australia and The Sydney Children's Hospitals Network.

Authors' Contributions
Conception and design: S. Suryani, H. Carol, C. Willman, P.J. Houghton, M.A. Smith, R.B. Lock
Development of methodology: S. Suryani, H. Carol, C.G. Mullighan, C. Willman, P.J. Houghton, R.B. Lock
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Suryani, L.S. Bracken, K.C.S. Sia, H. Carol, K. Evans, P.A. Dietrich, C.G. Mullighan, C. Willman, M.L. Loh, S.P. Hunger
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Suryani, L.S. Bracken, R.C. Harvey, K.C.S. Sia, H. Carol, K.G. Roberts, R.T. Kurmasheva, C.A. Billups, C. Willman, P.J. Houghton, M.A. Smith, R.B. Lock
Writing, review, and/or revision of the manuscript: S. Suryani, L.S. Bracken, R.C. Harvey, K.C.S. Sia, C. Willman, S.P. Hunger, P.J. Houghton, M.A. Smith, R.B. Lock
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Suryani, L.S. Bracken, I.-M. Chen, K.G. Roberts, M.L. Loh
Study supervision: S. Suryani, P.J. Houghton, R.B. Lock

Acknowledgments
The authors thank AstraZeneca Pharmaceuticals for providing AZD1480 and selumetinib and the Children's Oncology Group for the provision of the P9906 primary patient samples.

Grant Support
This research was funded by grants from the National Cancer Institute including NOI-CM-42216 and NOI-CM-91001-03 (to P.J. Houghton), CA98543 (COG Chair's grant), CA98413 (COG Statistical Center) and CA114766 (COG Specimen Banking; to S.P. Hunger). S. Suryani is supported by Postdoctoral Fellowships from the Leukaemia Foundation of Australia and the Cure Cancer Australia Foundation, and Early Career Fellowship from the Cancer Institute NSW. S.P. Hunger is the Ergen Family Chair in Pediatric Cancer.

R.B. Lock is supported by a Fellowship from the National Health and Medical Research Council.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 6, 2014; revised October 29, 2014; accepted November 13, 2014; published OnlineFirst December 10, 2014.

Figure 5.
In vivo efficacy of the combination of AZD1480 and selumetinib. Mice inoculated with PALLSD (A) or PAMDRM (B) were randomized to receive vehicle control or treatment with AZD1480 or selumetinib either as single agents or combination, as described in the Materials and Methods. Results are presented as the percentage of huCD45+ cells in the PB over time (left) or mouse EFS (right). Gray shading indicates the treatment period. C, pharmacodynamic analysis of ALL engrafted mice treated with AZD1480/selumetinib. Mice highly engrafted with PAMDRM cells were treated with vehicle control (M), AZD1480 (30 mg/kg), selumetinib (25 mg/kg), or selumetinib (25 mg/kg) 3 hours before AZD1480 (30 mg/kg). Spleens were collected at 2 and 9 hours after AZD1480 treatment. Vehicle-treated spleens were collected at the 9-hour timepoint. Protein extracts were analyzed by immunoblotting. Each lane is representative of a single spleen.


van bodegom d, zhong j, kopp n, dutta c, kim ms, bird l, et al. Differences in signaling through the B-cell signaling pathway in oncprotein CRF2 in response to TSLP and through mutantJak2. Blood 2012;120:2853–63.


Molecular Cancer Therapeutics

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Santi Suryani, Lauryn S. Bracken, Richard C. Harvey, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-14-0647

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2014/12/10/1535-7163.MCT-14-0647.DC1

Cited articles
This article cites 39 articles, 24 of which you can access for free at:
http://mct.aacrjournals.org/content/14/2/364.full.html#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
/content/14/2/364.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.